Source ID: C11
Original URL: https://news.bms.com/news/details/2026/Izalontamab-Brengitecan-Iza-Bren-Demonstrates-Statistically-Significant-and-Clinically-Meaningful-Improvements-in-Overall-Survival-and-Progression-Free-Survival-in-Patients-with-Triple-Negative-Breast-Cancer-and-Esophageal-Squamous-Cell-Carcinoma/default.aspx
Source date (attachment preserved): 2026-06-02
Data date (attachment preserved): 
Checked at: 2026-10-07T18:42:25+08:00
Timezone: Asia/Taipei
Retrieval mode: public_url_web_tool
Read level: BMS 原始公開公司公告；相關試驗設計、期中結果與合作段落，非期刊全文
Access result: 正常取得原 URL 公開正文
Original raw artifact SHA256: null

LOCATORS (actual reading positions):
公司公告 2026-06-02：L11、L14–16
Results from the Interim Analysis of PANKU-Breast02，L25–33
PANKU-Breast02 / PANKU-Esophagus01 及合作地域，L44；About iza-bren，L46–48

MINIMUM VERBATIM EXCERPT (only this block is source prose):
Outside of China, iza-bren is jointly developed by SystImmune and Bristol Myers Squibb under a collaboration and exclusive license agreement.

EXTRACTED FACTUAL FIELDS (not a reconstructed quotation):
[
  {
    "locator": "PANKU-Breast02 L26–29",
    "trial": "PANKU-Breast02",
    "country": "China",
    "phase": 3,
    "analysis": "prespecified interim",
    "population": "不可切除局部晚期或轉移 TNBC；晚期疾病接受過 1–2 線全身治療且曾用 taxane",
    "comparator": "physician choice chemotherapy",
    "N_iza_bren": 207,
    "N_comparator": 211,
    "median_OS_iza_bren": 15.9,
    "median_OS_comparator": 12.5,
    "unit": "months",
    "OS_HR": 0.6,
    "OS_HR_95ci": [
      0.42,
      0.85
    ],
    "median_follow_up_months": 11
  },
  {
    "locator": "L14–16, L44, L47–48",
    "phase3_regions": "中國的 PANKU-Breast02 與 PANKU-Esophagus01",
    "China_sponsor": "Sichuan Biokin Pharmaceutical",
    "outside_China_co_developers": [
      "SystImmune",
      "Bristol Myers Squibb"
    ],
    "targets": [
      "EGFR",
      "HER3"
    ],
    "payload_class": "Topo1i"
  }
]

SCOPE / PRECISE GAP (reviewer description, not source prose):
中國三期期中資料及中國以外 BMS/SystImmune 共同開發有直接支持；公司地圖把合作不分地域概括為「全球合作」過寬，建議精確化。未把公司公告提升成期刊證據。

Web refs: turn116view5, turn133view2, turn134view1, turn134view2